High expression of SQSTM1/p62 protein is associated with poor prognosis in epithelial ovarian cancer

Reiko Iwadate, Jun Inoue, Hitoshi Tsuda, Masashi Takano, Kenichi Furuya, Akira Hirasawa, Daisuke Aoki, Johji Inazawa

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

High expression of SQSTM1/p62 (p62) protein, which functions as a hub for various cellular signaling pathways, has been detected in several human cancers. However, the clinicopathological impact of high p62 expression is largely unknown in epithelial ovarian cancer (EOC). Here, the expression level of p62 in primary EOCs (n=266) was assessed by immunohistochemistry, and its clinical significance was analyzed. Univariate and multivariate analyses were used to determine the impact of p62 expression on overall survival. p62 was expressed in the cytoplasm (Cyto) and/or nucleus (Nuc) in primary EOCs, and an expression subtype (CytoHigh/NucLow), showing high expression in the cytoplasm but low expression in the nucleus, was significantly correlated with serous carcinoma (P<0.001), advanced stage (P=0.005), presence of residual tumor (P<0.001), and low overall survival rate (P=0.013). Furthermore, in serous carcinomas (n=107), the p62 CytoHigh/NucLow subtype was significantly correlated with low overall survival rate (P=0.019) as an independent factor (P=0.044). Thus, our findings suggest that high expression of cytoplasmic p62 may be a novel prognostic biomarker in EOC, particularly in serous carcinoma.

Original languageEnglish
Pages (from-to)295-301
Number of pages7
JournalActa Histochemica et Cytochemica
Volume47
Issue number6
DOIs
Publication statusPublished - 2014

Fingerprint

Cell signaling
Biomarkers
Tumors
Carcinoma
Cytoplasm
Proteins
Residual Neoplasm
Multivariate Analysis
Immunohistochemistry
Survival
Ovarian epithelial cancer
Neoplasms

Keywords

  • Epithelial ovarian cancer
  • Immunohistochemistry
  • P62
  • Prognosis
  • Serous carcinoma

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Physiology
  • Pathology and Forensic Medicine
  • Histology

Cite this

Iwadate, R., Inoue, J., Tsuda, H., Takano, M., Furuya, K., Hirasawa, A., ... Inazawa, J. (2014). High expression of SQSTM1/p62 protein is associated with poor prognosis in epithelial ovarian cancer. Acta Histochemica et Cytochemica, 47(6), 295-301. https://doi.org/10.1267/ahc.14048

High expression of SQSTM1/p62 protein is associated with poor prognosis in epithelial ovarian cancer. / Iwadate, Reiko; Inoue, Jun; Tsuda, Hitoshi; Takano, Masashi; Furuya, Kenichi; Hirasawa, Akira; Aoki, Daisuke; Inazawa, Johji.

In: Acta Histochemica et Cytochemica, Vol. 47, No. 6, 2014, p. 295-301.

Research output: Contribution to journalArticle

Iwadate, R, Inoue, J, Tsuda, H, Takano, M, Furuya, K, Hirasawa, A, Aoki, D & Inazawa, J 2014, 'High expression of SQSTM1/p62 protein is associated with poor prognosis in epithelial ovarian cancer', Acta Histochemica et Cytochemica, vol. 47, no. 6, pp. 295-301. https://doi.org/10.1267/ahc.14048
Iwadate, Reiko ; Inoue, Jun ; Tsuda, Hitoshi ; Takano, Masashi ; Furuya, Kenichi ; Hirasawa, Akira ; Aoki, Daisuke ; Inazawa, Johji. / High expression of SQSTM1/p62 protein is associated with poor prognosis in epithelial ovarian cancer. In: Acta Histochemica et Cytochemica. 2014 ; Vol. 47, No. 6. pp. 295-301.
@article{19e8e17f8e674adb843871862247435f,
title = "High expression of SQSTM1/p62 protein is associated with poor prognosis in epithelial ovarian cancer",
abstract = "High expression of SQSTM1/p62 (p62) protein, which functions as a hub for various cellular signaling pathways, has been detected in several human cancers. However, the clinicopathological impact of high p62 expression is largely unknown in epithelial ovarian cancer (EOC). Here, the expression level of p62 in primary EOCs (n=266) was assessed by immunohistochemistry, and its clinical significance was analyzed. Univariate and multivariate analyses were used to determine the impact of p62 expression on overall survival. p62 was expressed in the cytoplasm (Cyto) and/or nucleus (Nuc) in primary EOCs, and an expression subtype (CytoHigh/NucLow), showing high expression in the cytoplasm but low expression in the nucleus, was significantly correlated with serous carcinoma (P<0.001), advanced stage (P=0.005), presence of residual tumor (P<0.001), and low overall survival rate (P=0.013). Furthermore, in serous carcinomas (n=107), the p62 CytoHigh/NucLow subtype was significantly correlated with low overall survival rate (P=0.019) as an independent factor (P=0.044). Thus, our findings suggest that high expression of cytoplasmic p62 may be a novel prognostic biomarker in EOC, particularly in serous carcinoma.",
keywords = "Epithelial ovarian cancer, Immunohistochemistry, P62, Prognosis, Serous carcinoma",
author = "Reiko Iwadate and Jun Inoue and Hitoshi Tsuda and Masashi Takano and Kenichi Furuya and Akira Hirasawa and Daisuke Aoki and Johji Inazawa",
year = "2014",
doi = "10.1267/ahc.14048",
language = "English",
volume = "47",
pages = "295--301",
journal = "Acta Histochemica et Cytochemica",
issn = "0044-5991",
publisher = "Japan Society of Histochemistry and Cytochemistry",
number = "6",

}

TY - JOUR

T1 - High expression of SQSTM1/p62 protein is associated with poor prognosis in epithelial ovarian cancer

AU - Iwadate, Reiko

AU - Inoue, Jun

AU - Tsuda, Hitoshi

AU - Takano, Masashi

AU - Furuya, Kenichi

AU - Hirasawa, Akira

AU - Aoki, Daisuke

AU - Inazawa, Johji

PY - 2014

Y1 - 2014

N2 - High expression of SQSTM1/p62 (p62) protein, which functions as a hub for various cellular signaling pathways, has been detected in several human cancers. However, the clinicopathological impact of high p62 expression is largely unknown in epithelial ovarian cancer (EOC). Here, the expression level of p62 in primary EOCs (n=266) was assessed by immunohistochemistry, and its clinical significance was analyzed. Univariate and multivariate analyses were used to determine the impact of p62 expression on overall survival. p62 was expressed in the cytoplasm (Cyto) and/or nucleus (Nuc) in primary EOCs, and an expression subtype (CytoHigh/NucLow), showing high expression in the cytoplasm but low expression in the nucleus, was significantly correlated with serous carcinoma (P<0.001), advanced stage (P=0.005), presence of residual tumor (P<0.001), and low overall survival rate (P=0.013). Furthermore, in serous carcinomas (n=107), the p62 CytoHigh/NucLow subtype was significantly correlated with low overall survival rate (P=0.019) as an independent factor (P=0.044). Thus, our findings suggest that high expression of cytoplasmic p62 may be a novel prognostic biomarker in EOC, particularly in serous carcinoma.

AB - High expression of SQSTM1/p62 (p62) protein, which functions as a hub for various cellular signaling pathways, has been detected in several human cancers. However, the clinicopathological impact of high p62 expression is largely unknown in epithelial ovarian cancer (EOC). Here, the expression level of p62 in primary EOCs (n=266) was assessed by immunohistochemistry, and its clinical significance was analyzed. Univariate and multivariate analyses were used to determine the impact of p62 expression on overall survival. p62 was expressed in the cytoplasm (Cyto) and/or nucleus (Nuc) in primary EOCs, and an expression subtype (CytoHigh/NucLow), showing high expression in the cytoplasm but low expression in the nucleus, was significantly correlated with serous carcinoma (P<0.001), advanced stage (P=0.005), presence of residual tumor (P<0.001), and low overall survival rate (P=0.013). Furthermore, in serous carcinomas (n=107), the p62 CytoHigh/NucLow subtype was significantly correlated with low overall survival rate (P=0.019) as an independent factor (P=0.044). Thus, our findings suggest that high expression of cytoplasmic p62 may be a novel prognostic biomarker in EOC, particularly in serous carcinoma.

KW - Epithelial ovarian cancer

KW - Immunohistochemistry

KW - P62

KW - Prognosis

KW - Serous carcinoma

UR - http://www.scopus.com/inward/record.url?scp=84919793643&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919793643&partnerID=8YFLogxK

U2 - 10.1267/ahc.14048

DO - 10.1267/ahc.14048

M3 - Article

VL - 47

SP - 295

EP - 301

JO - Acta Histochemica et Cytochemica

JF - Acta Histochemica et Cytochemica

SN - 0044-5991

IS - 6

ER -